SEBIVO

This brand name is authorized in Estonia, Hong Kong SAR China, Lithuania, Poland, Romania, Singapore.

Active ingredients

The drug SEBIVO contains one active pharmaceutical ingredient (API):

1	Telbivudine UNII 2OC4HKD3SF - TELBIVUDINE
	Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase. It is efficiently phosphorylated by cellular kinases to the active triphosphate form. Incorporation of telbivudine-5'-triphosphate into viral DNA causes DNA chain termination, resulting in inhibition of HBV replication.
	Read more about Telbivudine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SEBIVO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AF11	Telbivudine	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
Discover more medicines within J05AF11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1294781, 1367940, 1437836
HK	Department of Health Drug Office	55624
LT	Valstybinė vaistų kontrolės tarnyba	1030594, 1030595, 1036163
PL	Rejestru Produktów Leczniczych	100206276, 100219422
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64471001, W64471002
SG	Health Sciences Authority	13304P